Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043509007> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3043509007 endingPage "184" @default.
- W3043509007 startingPage "177" @default.
- W3043509007 abstract "(Objective) We retrospectively evaluated the clinical efficacy and safety of abiraterone acetate (AA) in patients with castration-resistant prostate cancer (CRPC). (Methods) We analyzed the clinical records of 50 patients who had received AA in Gunma Cancer Center between October 2014 and June 2017. We assessed the response of prostate-specific antigen (PSA) to AA, and analyzed the association between overall survival and various parameters, including the types of primary hormonal therapy, PSA level, Gleason score, time to CRPC, prior treatment with enzalutamide (Enz) and docetaxel, and sites of metastases. (Results) The median patient age was 74.5 years and median PSA level at baseline was 15.9 ng/ml; 39 (78%) patients had Gleason score ≥8. Eleven (45.8%) of the 24 docetaxel-naïve patients achieved >50% reduction in PSA level from baseline as opposed to one (4.5%) of the 22 patients previously treated with docetaxel.Eleven (55%) of the 20 Enz-naïve patients achieved >50% reduction in PSA level from baseline compared to one (3.8%) of the 26 patients previously treated with Enz. The overall survival of the group with time to CRPC >12 months was significantly longer than that of the group with time to CRPC <12 months (p=0.035). In general, AA was tolerated; the most frequently reported adverse events included liver dysfunction (22%) and fatigue (6%). (Conclusion) Our results suggest that AA is tolerated and may be suitable for patients with time to CRPC >12 months." @default.
- W3043509007 created "2020-07-23" @default.
- W3043509007 creator A5028259838 @default.
- W3043509007 creator A5051612616 @default.
- W3043509007 creator A5061598428 @default.
- W3043509007 creator A5067929923 @default.
- W3043509007 creator A5070852103 @default.
- W3043509007 date "2019-07-20" @default.
- W3043509007 modified "2023-10-17" @default.
- W3043509007 title "CLINICAL OUTCOMES OF ABIRATERONE ACETATE FOR TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A RETROSPECTIVE ANALYSIS" @default.
- W3043509007 doi "https://doi.org/10.5980/jpnjurol.110.177" @default.
- W3043509007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32684578" @default.
- W3043509007 hasPublicationYear "2019" @default.
- W3043509007 type Work @default.
- W3043509007 sameAs 3043509007 @default.
- W3043509007 citedByCount "0" @default.
- W3043509007 crossrefType "journal-article" @default.
- W3043509007 hasAuthorship W3043509007A5028259838 @default.
- W3043509007 hasAuthorship W3043509007A5051612616 @default.
- W3043509007 hasAuthorship W3043509007A5061598428 @default.
- W3043509007 hasAuthorship W3043509007A5067929923 @default.
- W3043509007 hasAuthorship W3043509007A5070852103 @default.
- W3043509007 hasBestOaLocation W30435090071 @default.
- W3043509007 hasConcept C121608353 @default.
- W3043509007 hasConcept C126322002 @default.
- W3043509007 hasConcept C126894567 @default.
- W3043509007 hasConcept C143998085 @default.
- W3043509007 hasConcept C197934379 @default.
- W3043509007 hasConcept C2775832370 @default.
- W3043509007 hasConcept C2776551883 @default.
- W3043509007 hasConcept C2777899217 @default.
- W3043509007 hasConcept C2780192828 @default.
- W3043509007 hasConcept C2781190966 @default.
- W3043509007 hasConcept C2781406297 @default.
- W3043509007 hasConcept C61367390 @default.
- W3043509007 hasConcept C71924100 @default.
- W3043509007 hasConceptScore W3043509007C121608353 @default.
- W3043509007 hasConceptScore W3043509007C126322002 @default.
- W3043509007 hasConceptScore W3043509007C126894567 @default.
- W3043509007 hasConceptScore W3043509007C143998085 @default.
- W3043509007 hasConceptScore W3043509007C197934379 @default.
- W3043509007 hasConceptScore W3043509007C2775832370 @default.
- W3043509007 hasConceptScore W3043509007C2776551883 @default.
- W3043509007 hasConceptScore W3043509007C2777899217 @default.
- W3043509007 hasConceptScore W3043509007C2780192828 @default.
- W3043509007 hasConceptScore W3043509007C2781190966 @default.
- W3043509007 hasConceptScore W3043509007C2781406297 @default.
- W3043509007 hasConceptScore W3043509007C61367390 @default.
- W3043509007 hasConceptScore W3043509007C71924100 @default.
- W3043509007 hasIssue "3" @default.
- W3043509007 hasLocation W30435090071 @default.
- W3043509007 hasLocation W30435090072 @default.
- W3043509007 hasOpenAccess W3043509007 @default.
- W3043509007 hasPrimaryLocation W30435090071 @default.
- W3043509007 hasRelatedWork W1980998207 @default.
- W3043509007 hasRelatedWork W2464380321 @default.
- W3043509007 hasRelatedWork W2568045406 @default.
- W3043509007 hasRelatedWork W2770702948 @default.
- W3043509007 hasRelatedWork W2776594178 @default.
- W3043509007 hasRelatedWork W3023947295 @default.
- W3043509007 hasRelatedWork W3181573761 @default.
- W3043509007 hasRelatedWork W3197069188 @default.
- W3043509007 hasRelatedWork W4226040508 @default.
- W3043509007 hasRelatedWork W4229076799 @default.
- W3043509007 hasVolume "110" @default.
- W3043509007 isParatext "false" @default.
- W3043509007 isRetracted "false" @default.
- W3043509007 magId "3043509007" @default.
- W3043509007 workType "article" @default.